Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance.

Nature microbiology·2026
Same author

The role of integrins in T cell-mediated resistance to <i>Cryptosporidium parvum</i>.

bioRxiv : the preprint server for biology·2026
Same author

The revised Cryptosporidium life cycle offers opportunities for fundamental and translational advances.

Trends in parasitology·2026
Same author

Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions.

bioRxiv : the preprint server for biology·2026
Same author

An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy.

Cell reports·2025
Same author

IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Jun 15, 2025

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

10.6K

De-coupling immune parameters and toxicity associated with IL-12 agonism.

Zachary R Lanzar1, Daniel L Aldridge1, Bhargavi Jayaraman2

  • 1Department of Pathobiology, University of Pennsylvania, Philadelphia, PA 19104, USA.

Cell Reports
|June 13, 2025
PubMed
Summary

Modifying Interleukin-12 (IL-12) agonists, like IL-12Fc, can boost immune resistance to infection. Fine-tuning IL-12 signaling avoids adverse effects, demonstrating a safer approach to immune modulation.

Keywords:
CP: Immunologyhematopoeisisinfectioninnate and adaptive immunityinterleukin-12toxicity

More Related Videos

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

196
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

547

Related Experiment Videos

Last Updated: Jun 15, 2025

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

10.6K
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

196
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

547

Area of Science:

  • Immunology
  • Pharmacology
  • Toxicology

Background:

  • Interleukin-12 (IL-12) is crucial for immune responses, stimulating natural killer (NK) and T cells to produce interferon gamma (IFN-γ).
  • Clinical applications of IL-12 are limited by adverse events associated with NK cell activation.
  • Developing IL-12 agonists with modified pharmacokinetics is essential for therapeutic advancement.

Purpose of the Study:

  • To investigate the impact of half-life-extended IL-12 agonists, specifically full (IL-12Fc) and partial (IL-12 3x AlaFc) agonists, on the immune system.
  • To compare the immunomodulatory and pathological effects of these distinct IL-12 agonists.
  • To explore the potential of fine-tuned IL-12 agonism for enhancing host defense without inducing toxicity.

Main Methods:

  • Treatment of naive mice with serially administered IL-12Fc and IL-12 3x AlaFc.
  • Assessment of systemic IFN-γ production, multi-organ pathology, and alterations in myelopoiesis.
  • Evaluation of immune cell activation (NK, CD4+, CD8+ T, NKT cells) and IFN-γ's role in toxicity and myelopoiesis.

Main Results:

  • IL-12Fc induced systemic IFN-γ, multi-organ pathology, and myelopoiesis, activating NK, CD4+, CD8+ T, and NKT cells.
  • IFN-γ was not required for IL-12Fc-induced systemic toxicity, though it facilitated myelopoiesis.
  • IL-12 3x AlaFc activated CD4+ and CD8+ T cells, induced myelopoiesis, and importantly, avoided overt disease.
  • Differential activities of IL-12 agonists were harnessed to enhance resistance to infection.

Conclusions:

  • A threshold of IL-12 signaling is tolerated under steady-state conditions.
  • Fine-tuning IL-12 agonism can enhance resistance to infection without triggering pathology.
  • Partial IL-12 agonists offer a promising strategy for immune modulation with reduced adverse effects.